MrMugsy wrote: Doccole wrote: Hello all,
We await news to rise this out of the depths of the underwater abyss! I have averaged down, even with a large amount of shares. I hope the strategy pays off. To be honest, my hopes aren't high.
The question is- what news will make this rise? (Before phase2, allegedly in Q4)
Even if prices rise my positon will be to hold to the conclusion of phase 2. I've been on this hill long enough and I am good to die on it at this point.
Hahaha - let's avoid the dying part but I agree with that comment !!!
I wouldn't worry about the rise before P2 as we can't guess that with any accurately anyway.
Question is - what is the value to a Big Pharma buyer? That depends on where the drug stands after P2 and how far we've progressed with other drugs should we see a P2 win.
With success ... negotiations likely look different if/when they start-up again
-------------
By the time we get to the end of P2 we should know ...
- where the acute potential is for 346
- what 352 can do and how far along it is - what the strategy is
- what IBD can do and what the strategy looks like
- if we're making headway on chronic and if it's still under investigation or ready to move forward
All of those developments add to the discussions with Big Pharma
-------------
Like I've said before ... my share accumulation in the 60-70 cent range is partly because I see a chronic victory of some sort in our future. Right or wrong I look at it this way ...
- chronic victory with higher dose but lower frequency of use (OR)
- combination (hybrid) regimen where OTENA is used at some freq. with a Naproxen regimen (OR)
- OTENA used only when the pain flares up - not to be used more than xxxxxx (kind of thing)
The first is the best option for value if it bypasses the liver confusion - and - the last option probably doesn't need FDA approval but can happen on Doctor's prescription IF we get an acute win.
--------------
Note that what happens with OTENA chronic will likely dictate how our other drugs like IBD, Respiratory, Neuro-inflammatory and ATB-340 are pursued.
One final note ... depending what they learn from chemistry development with IBD - that could also lead to future design options for our other drugs.
--------------
Unfortunately this is drug development and we have to wait for it - some seem to think they were promised riches but isn't the case. They let anger cloud their minds while they should have been planning their next steps.
But - these products and our IP seem to be quite resilient ... another thing I like here. This should be well noted by Big Pharma when they get to negotiations as we are witnessing first hand the ability to go after new IP.
True - we've lost time - but beyond that ... I don't think we've lost much else (yet).
With any luck, the time that seems to be lost - turns out to be time well spent in increasing the IP value to Big Pharma.
It's now a waiting game !!!!